ArticleExpert opinion on pharmacotherapy2003
Losartan for LIFE in hypertension with left ventricular hypertrophy?
Article in Expert opinion on pharmacotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When ACE inhibitors are used to lower blood pressure to the same degree as beta-adrenoceptor antagonists or calcium channel blockers, ACE inhibitors do not seem to have additional benefits to these agents. In the Losartan Intervention for End Point Reduction in Hypertension study (LIFE), losartan was compared to atenolol in hypertensives with the additional risk factor of left ventricular hypertrophy (LVH). For similar effects on blood pressure, losartan had a greater benefit on the primary composite end point (cardiovascular mortality, stroke and myocardial infarction) than atenolol in the hypertensives with LVH, including a prespecified subgroup of patients with additional diabetes mellitus. Losartan also had a greater ability to reverse LVH than atenolol. Thus, losartan should become the standard treatment for hypertension when LVH is present.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.